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Cohort	 studies	 demonstrated	 that	 among	NAFLD	populations,	
those	with	non‐alcoholic	steatohepatitis	 (NASH)	have	a	higher	risk	
of	 fibrosis	 progression,	 and	 that	 the	 presence	 of	 severe	 liver	 fi‐
brosis	 is	 the	main	driver	of	hepatic	and	extra‐hepatic	prognosis.2,3 
Even	if	 liver	biopsy	is	considered	the	diagnostic	gold	standard,	the	
availability	of	non‐invasive	markers	 to	be	used	 in	NAFLD	patients	
to	 predict	NASH	 and/or	 severity	 of	 fibrosis	 represents	 a	 relevant	





for	 the	 non‐invasive	 assessment	 of	 fibrosis	 (eg	 ‘aspartate	 amino‐





sient	elastography	 (FibroScan)	 is	a	widely	diffused	 tool,	even	 if	 its	
accuracy	can	be	influenced	by	obesity	and	severity	of	steatosis.7,8
Circulating	 RNAs	 in	 plasma	 or	 serum	 have	 been	 attracting	
exponential	 attention	 as	 novel	 non‐invasive	 diagnostic	 biomark‐








Several	 studies	 have	 highlighted	 the	 stability	 of	 lncRNAs	 and	
mRNAs,	also	under	various	experimental	and	pre‐analytical	oppres‐
sive	 conditions,	 including	 multiple	 freeze‐thaw	 cycles,	 prolonged	
incubation	 at	 room	 temperature	 (up	 to	 24h),	 exogenous	 RNAse	
treatments,	 time	 delay	 in	 processing	 of	 blood	 after	 venipuncture,	
low/high	pH.10,12‐15




Two	 very	 recent	 studies	 reported	 the	 aberrant	 expression	 of	
long	non‐coding	RNAs	(lncRNAs)	in	liver	tissue	of	NAFL/NASH	pa‐






















•	 Our	 study	 suggests	 the	use	of	 coding	 and	non‐coding	
RNA	as	non‐invasive	biomarkers	of	NAFLD	and	fibrosis	

























insulin	 secretion.21	 Numerous	 studies	 performed	 high‐throughput	







are	 able	 to	 identify	NAFLD	patients	with	NASH	 and/or	 advanced	
fibrosis.
2  | MATERIAL S AND METHODS
2.1 | Study subjects















study.	 Further	 information	 regarding	 histopathological	 evaluation	
and	sample	processing	can	be	found	as	Supplementary Data.








4  | MICROARR AY ANALYSIS
High‐throughput	 profiling	 of	 serum	 coding/non‐coding	 RNA,	
through	microarray	 technology	 by	Clariom	D	Pico	Assay	 (Thermo	





To	 understand	 the	 function	 of	 statistically	 significant	 deregulated	
transcripts	 for	 each	 comparison	 (mild	 NAFLD	 vs	 CTRL,	 severe	
NAFLD	 vs	 CTRL,	 severe	 vs	mild	NAFLD),	 we	 performed	 pathway	
enrichment	 analysis	 through	 Transcriptome	 Analysis	 Console	 v.	 4	
which	 retrieves	 canonical	 biological	 pathways	 from	WikiPathways	
database	 and	 establishes	 P‐values	 using	 two‐sided	 Fisher's	 Exact	
Test	(P	<	0.05).







7  | SINGLE RE AL‐TIME PCR A SSAYS
Validation	 of	 candidate	 coding/non‐coding	 RNAs	 both	 in	 an	 in‐
dependent	 internal	 cohort	 of	 88	 study	 subjects	 (63	 NAFLD	 and	
25	 CTRL)	 and	 an	 in	 external	 cohort	 of	 50	 NAFLD	 patients	 was	
performed	 through	 real‐time	 PCR	 assays	 (Power	 SYBR	 Green	
RNA‐to‐CT1‐Step	 Kit	 Thermo	 Fisher	 Scientific)	 according	 to	 the	
manufacturer's	 protocol.	 Candidate	 transcripts	 were	 selected	 ac‐
cording	to	the	following	three	criteria:	(i)	high	levels	of	fluorescence	
microarray	signals;	(ii)	low	P‐value	in	severe	NAFLD	vs	mild	NAFLD	






Differentially	 expressed	 (DE)	 coding	 and	 non‐coding	 RNA	 identi‐
fication	 was	 performed	 by	 Transcriptome	 Analysis	 Console	 (TAC)	
Software	v.4,	according	to	the	following	parameters:	Analysis	Type:	
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In	 order	 to	 identify	 novel	 potential	 biomarker	 signatures	 associ‐
ated	with	NAFLD	spectrum,	we	performed	a	whole	transcriptome	
analysis	 in	sera	 from	four	mild	NAFLD	patients	 (NAS	≤	4;	F	=	0),	
four	 severe	 NAFLD	 patients	 (NAS	 ≥	 5;	 F	 =	 3)	 and	 four	 healthy	
matched	controls.	 Statistically	 significant	deregulated	 transcripts	
in	each	comparison	are	represented	as	scatter	plots	in	Figure	1A.	
We	 identified:	 990	 deregulated	 transcripts	 in	 mild	 NAFLD	 vs	
CTRL	comparison;	1842	deregulated	transcripts	in	severe	NAFLD	
vs	CTRL	 comparison	 and	1098	deregulated	 transcripts	 in	 severe	
NAFLD	 vs	 mild	 NAFLD	 comparison.	 Fold	 change	 (FC)	 deregula‐
tion	 counts	 of	 statistically	 significant	DE	 coding	 and	 non‐coding	
RNAs	(ANOVA	Method:	ebayes	P	<	0.05)	for	each	comparison	are	






9  | PATHWAY ANALYSIS OF 
DIFFERENTIALLY E XPRESSED TR ANSCRIPTS
To	 explore	 the	 potential	 functions	 of	 deregulated	 transcripts,	
we	 identified	 significantly	 enriched	 biological	 pathways	 through	
Transcriptome	Analysis	Console.	This	bioinformatics	analysis	dem‐
onstrated	that	DE	transcripts	were	statistically	significant	(Fisher's	
Exact	 Test	 P	 <	 0.05)	 associated	 with	 several	 signalling	 pathways	
known	to	be	 involved	in	NASH/Fibrosis	pathogenesis	 including	 in‐
flammatory	pathways	(eg	interleukins	signalling	pathways),	metabo‐
lism	deregulation	 (eg	 electron	 transport	 chain,	 TCA	 cycle	 nutrient	
utilization,	Sterol	Responsive	Element	Binding	Protein,	insulin	signal‐
ling),	cell	death	 (eg	apoptosis,	 ferroptosis),	UPR	stress	 (eg	proteas‐
ome	degradation,	cytoplasmic	ribosomal	proteins),	and	extracellular	
matrix	biosynthesis/fibrosis	(eg	collagen	biosynthesis	and	modifying	
enzymes,	 VEGFA‐VEGFR	 signalling	 pathway,	 EGF/EGFR	 signalling	
pathway)	(Figure	1B).
10  | VALIDATION BY qPCRs
In	order	to	confirm	microarray	data,	we	analysed	the	expression	of	
candidate	transcripts	through	qPCRs	in	a	 larger	 internal	 independ‐
ent	cohort	of	88	subjects	 (CTRL	=	25	and	NAFLD	=	63)	and	 in	an	
external	 cohort	 of	 50	 NAFLD	 patients.	 Clinical	 and	 demographic	
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characteristics	of	each	cohort	subjects	are	reported	in	Table	1.	We	
selected	the	following	transcripts:	HBA2,	UBE2V1,	BNIP3L	coding	
RNAs,	 RP11‐128N14.5	 lncRNA	 and	 TGFB2/TGFB2‐OT1	 coding/
non‐coding	RNA.	We	chose	these	transcripts	because:	(i)	they	pre‐
sented	high	 levels	of	 fluorescence	microarray	signals;	 (ii)	 they	pre‐
sented	a	low	P‐value	in	severe	NAFLD	vs	mild	NAFLD	comparison	










RP11‐128N14.5,	 BNIP3L	 and	 TGFB2/TGFB2‐OT1	 in	 serum	 sam‐
ples	of	patients	with	a	NAS	≥	5	with	respect	to	those	with	NAS	≤	4	
(Figure	 2A).	 Moreover,	 taking	 into	 account	 NASH	 diagnosis	 only	
RP11‐128N14.5	reached	statistical	significance	(NOT	NASH	n	=	18	
vs		NASH	n	=	45	FC	=	7.13,	P	=	2.00E‐02)	(Figure	2B).















The	 up‐regulation	 of	 UBE2V1,	 RP11‐128N14.5,	 BNIP3L	 and	
TGFB2/TGFB2‐OT1	in	NAS	≥	5	vs	NAS	≤	4	patients,	RP11‐128N14.5	
in	 NASH	 vs	 simple	 steatosis	 and	 the	 up‐regulation	 of	 HBA2,	 and	




11  | VALIDATED TR ANSCRIPTS ARE 
A SSOCIATED WITH CLINIC AL MARKERS 
AND HISTOLOGIC AL SCORES
We	analysed	whether	 ‐ΔCt	values	of	validated	transcripts	were	
associated	 through	 a	 linear	 regression	 relationship	 both	 with	








with	 AST,	 Kleiner	 ballooning,	 NAS	 and	 fibrosis	 scores	 (Figure	 S10).	
TGFB2/TGFB2‐OT1	was	associated	through	a	positive	linear	regres‐
sion	 relationship	with	 FIB‐4,	 Liver	 Stiffness	Measurements,	 Kleiner	
lobular	inflammation	and	fibrosis	scores	(Figure	S11).	Finally,	we	found	
an	 inverse	 linear	 relationship	among	sherveebu	AC020558.4	expres‐
sion	levels	and	triglycerides	(Figure	S12)	and	between	HBA2	and	total	
cholesterol	levels.	P‐values	and	R2	values	are	reported	in	Table	S2.
12  | E XPRESSION ANALYSIS OF LIVER 
TISSUES AND IN VITRO MODEL S








used	an	 in	vitro	model	 that	we	already	used	 in	a	previous	work.27 
HepG2	cells	were	exposed	for	48	h	to	a	mixture	of	oleate:palmitate	
(OA:PA)	 or	 only	 to	 palmitate	 (PA),	 to	 simulate	 simple	 steatosis	 or	
NASH	respectively.27
As	 shown	 in	 Figure	 4A	 in	 liver	 tissue,	 we	 observed	 a	 statisti‐
cally	 significant	 up‐regulation	 of	 UBE2V1	mRNA,	 RP11‐128N14.5	
lncRNA	 and	 TGFB2/TGFB2‐OT1	 coding/non‐coding	 RNA	 in	 se‐







those	 treated	with	OA:PA	 and	 to	 controls	 (Figure	4B).	Differently	
from	 tissue	 data,	 intracellular	 HBA2	 expression	 levels	 were	 unaf‐
fected	 by	 free	 fatty	 acid	 treatments	 and	 sherveebu	 AC020558.4	
ncRNA	presented	a	statistical	significant	increasing	trend	of	expres‐
sion	ranging	from	NAFL	to	NASH	in	vitro	models.
At	 the	 extracellular	 level,	 UBE2V1	 mRNA	 and	 sherveebu 
AC020558.4	 ncRNA	 were	 statistically	 significantly	 deregulated	
only	 in	 PA	 vs	 OA:PA	 condition	 comparison;	 medium‐secreted	
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13  | RECEIVER OPER ATING 
CHAR AC TERISTIC S CURVE ANALYSIS
By	 performing	 ROC	 curve	 analysis,	 we	 investigated,	 the	 di‐
agnostic	 performance	 of	 validated	 transcripts	 for	 F	 =	 3‐4	 or	
NAS	 ≥	 5	 patient	 identification	 in	 NAFLD	 validation	 cohorts.	
The	 transcripts	 that	 reached	 statistical	 significance	 in	 ROC	
curve	 analysis	 were:	 (I)TGFB2/TGFB2‐OT1	 (internal	 cohort:	
AUC	 =	 0.797,	 95%	 CI	 =	 0.675‐0.918,	 sensitivity	 =	 65%,	 speci‐
ficity	=	81.3%,	P	 =	3.5E‐04;	 external	 cohort:	AUC	=	0.786,	95%	
CI	 =	 0.623‐0.950,	 sensitivity	 =	 62.5%,	 specificity	 =	 94.4%,	
P	=	4.4E‐03)	in	F	=	3‐4	vs	F	=	0‐2	comparison;	(II)	RP11‐128N14.5	












NAFLD patients vs 
external cohort
Clinical	variables
Age	(years) 48.00 ± 10.01 50.65 ± 12.35 52.76 ± 10.00 0.252 0.358
Gender	(%	of	male) 32% 59% 70% 0.043 0.298
BMI	(kg/m2) 24.14 ± 2.14 29.87 ± 4.57 29.08 ± 3.83 0.00000011 0.378
AST	(IU/I) 20.63 ± 5.81 46.50 ± 27.77 41.10 ± 29.03 0.00002 0.348
ALT	(IU/I) 20.71 ± 7.21 78.03 ± 67.09 57.44 ± 46.45 0.0001 0.091
Platelets	(×109/I) 248.50 ± 36.96 236.18 ± 87.44 202 ± 72.38 0.234 0.063
Total	cholesterol	(mg/dL) 200.94 ± 39.90 191.42 ± 39.74 186.39 ± 41.58 0.387 0.556
HDL	cholesterol	(mg/dL) 61.50 ± 10.17 48.54 ± 16.44 46.18 ± 14.31 0.035 0.460
Triglycerides	(mg/dL) 93.88 ± 30.27 136.93 ± 74.29 154.90 ± 70.63 0.023 0.231
FIB‐4	score  1.52 ± 1.36 1.61 ± 0.96  0.756
APRI	score  0.38 ± 0.35 0.59 ± 0.58  0.036
LSM	–	KPa  12.27 ± 11.90    
Histology
Kleiner	steatosis	grade	(0‐3)
0  ‐ 1	(2%)  0.352
1  19	(30%) 11	(22%)  
2  24	(38%) 17	(34%)  
3  29	(46%) 21	(42%)  
Kleiner	lobular	inflammation	score	(0‐3)
0  ‐‐‐ 3	(6%)  0.550
1  37	(59%) 15	(30%)  
2  21(33%) 27	(54%)  
3  5	(8%) 5	(10%)  
Kleiner	Ballooning	score	(0‐2)
0  18	(29%) 16	(32%)  0.510
1  33	(52%) 27	(54%)  
2  12	(19%) 7	(14%)  
Kleiner	NAS		(0‐8)
≤4  38	(60%) 23	(46%)  0.598
≥5  25	(40%) 27	(54%)  
Kleiner	fibrosis	stage	(0‐4)
0‐2  37	(59%) 26	(52%)  0.275
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F I G U R E  4  Histograms	of	coding/noncoding	RNA	expression	levels	observed	in	liver	biopsies	(n	=	12,	four	CTRL,	four	mild	NAFLD:	
NAS	≤	4	F	=	0,	four	severe	NAFLD	NAS	SCORE	≥	5	F	=	3)	(panel	A)	and	in	OA:PA	and	PA	treated	HepG2	with	respect	to	controls	at	
intracellular	and	extracellular	levels	(panel	B).	OA:PA	=	oleate:palmitate;	PA	=	palmitate;	CTRL	=	control.	FC	=	fold	change
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(internal	 cohort:	 AUC	 =	 0.706,	 95%	 CI	 =	 0.554‐0.857,	 sensitiv‐
ity	 =	 73.7%,	 specificity	 =	 70.4%,	 P	 =	 1.9E‐02;	 external	 cohort:	
AUC	=	0.694,	95%	CI	=	0.545‐0.843,	sensitivity	=	78.3%,	specific‐
ity	=	63%,	P	=	2.0E02)	and	BNIP3L	(internal	cohort:	AUC	=	0.676,	




It	 is	 important	 to	 note	 that	 TGFB2/TGFB2‐OT1	 expression	
levels	were	associated	with	the	blood‐based	 index	FIB‐4	and	LSM	
used	in	clinical	practice	for	non‐invasive	diagnosis	of	F	=	3‐4	stages	
and	 histological	 Kleiner	 fibrosis	 stage.	 Comparison	 of	 the	 AUCs	
revealed	 the	 combinations	 TGFB2/TGFB2‐OT1	 plus	 FIB‐4	 (inter‐
nal	cohort:	AUC	=	0.891,	95%	CI	=	0.799‐0.982,	sensitivity	=	80%,	
specificity	 =	 87.5%,	 P	 =	 3.0E‐06;	 external	 cohort:	 AUC	 =	 0.889,	
95%	 CI	 =	 0.771‐0.998,	 sensitivity	 =	 87.5%,	 specificity	 =	 83.3%,	
P	 =	 1.1E‐04)	 or	 TGFB2/TGFB2‐OT1	 plus	 LSM	 (AUC	 =	 0.892,	
95%	 CI	 =	 0.802‐0.983,	 sensitivity	 =	 80%,	 specificity	 =	 90.6%,	
P	=	2.0E‐06)	were	superior	to	APRI	 (internal	cohort:	AUC	=	0.759,	




specificity	 =	 93.8%,	 P	 =	 1.3E‐0.4;	 external	 cohort:	 AUC	 =	 0.839,	
95%	 CI	 =	 0.698‐0.979,	 sensitivity	 =	 93.8%,	 specificity	 =	 66.7%,	
P	=	7.7E‐04);	TGB2/TGFB2‐OT1	(internal	cohort:	AUC	=	0.797,	95%	
CI	=	0.675‐0.918,	sensitivity	=	65%,	specificity	=	81.3%,	P	=	3.5E‐04;	
external	 cohort:	 AUC	 =	 0.786,	 95%	 CI	 =	 0.623‐0.950,	 sensitiv‐
ity	=	62.5%,	specificity	=	94.4%,	P	=	4.4E‐03)	and	LSM	(AUC	=	0.841,	
95%	 CI	 =	 0.723	 −0.960,	 sensitivity	 =	 85%,	 specificity	 =	 81.3%,	
P	=	4.0E‐05)	(Figure	5,	Figure	S13).










In	 NASH	 vs	 not	 NASH	 comparison,	 RP11‐128N14.5	 did	 not	
reach	 statistical	 significance;	 however,	 its	 AUC	 (internal	 cohort:	
AUC	 =	 0.632,	 95%	 CI	 =	 0.477‐0.787,	 sensitivity	 =	 86.7%,	 spec‐
ificity	 =	 38.9%,	 P	 =	 1.0E‐01;	 external	 cohort:	 AUC	 =	 0.650,	
95%	 CI	 =	 0.480‐0.819,	 sensitivity	 =	 53.3%,	 specificity	 =	 4.3%,	
P	 =	 9.7E‐02)	 was	 superior	 with	 respect	 to	 ALT	 (internal	 cohort:	
AUC	 =	 0.412,	 95%	 CI	 =	 0.258‐0.567,	 sensitivity	 =	 25%,	 spec‐
ificity	 =	 83.3%.	 P	 =	 2.9E‐01,	 external	 cohort:	 AUC	 =	 0.567,	
95%	 CI	 =	 0.390‐0.744,	 sensitivity	 =	 57.7%,	 specificity=73.3%,	
P	=	4.8E‐01)	and	similar	to	AST	(AUC	=	0.558,	95%	CI	=	0.397‐0.720,	
sensitivity	=	69.2%,	specificity	=	55.6%,	P	=	4.8E‐01;	external	co‐
hort	 AUC	 =	 0.672,	 95%	 CI	 =	 0.503‐0.842,	 sensitivity	 =	 62.5%,	
specificity	 =	 80%;	P	 =	 7.3E‐02).	 Combination	 of	 RP11‐128N14.5	
with	AST	or	ALT	in	both	cohorts	decreased	its	AUC:	0.5	P	=	1.
14  | DISCUSSION











tially	 linked	 to	 NASH	 progression	 and	 fibrogenic	 pathways.	 The	
potential	 of	 validated	 transcripts	 for	 predicting	 disease	 severity	






















and	 TGFB2/TGFB2‐OT1	 (P	 =	 3.10E‐02);	 Kleiner	 ballooning	 score	
correlated	 with	 UBE2V1	 (P	 =	 4.50E‐02),	 BNIP3L	 (P	 =	 2.60E‐02),	
RP11‐128N14.5	 (P	 =	 1.20E‐02);	 Kleiner	 fibrosis	 score	 correlated	















Interestingly,	 switching	 from	 control	 conditions	 to	 OA:PA	 and	
PA‐treated	 cells,	 the	RNAs	 secreted	 into	 the	medium	partially	 re‐
flected	 the	 expression	 trends	 observed	 in	 serum	 samples	 from	
healthy	controls	and	mild	and	severe	NAFLD	patients.	In	our	in	vitro	
model,	we	also	found	that	the	cellular	expression	of	mRNA	UBE2V1,	
lncRNA	 RP11‐128N14.5,	 ncRNA	 sherveebu	 AC020558.4,	 TGFB2/
TGFB2‐OT1	 coding/non‐coding	 RNA	 progressively	 increased,	
switching	 from	CTRL	 to	OA:PA	and	PA	 conditions.	 Saturated	 free	
fatty	acid	palmitate,	which	is	mainly	responsible	for	lipotoxic	effects	
compared	to	unsaturated	fatty	acid	oleate,	seems	to	trigger	an	 in‐








function	 and	 involvement	 in	 NAFLD	 spectrum	 have	 not	 yet	 been	
characterized.
NASH	affects	not	only	hepatocytes	 in	 the	 liver,	but	 it	 involves	
several	 other	 hepatic	 cell	 types	 (eg	 Hepatic	 Stellate	 Cells,	 innate	
immune	 liver	 cells:	Kupffer	 cells,	 natural	 killer	 cells)	 and	other	 tis‐
sues/organs	 (eg	gut,	adipose	tissue,	circulating	 inflammatory	cells);	
therefore	 analysed	 transcript	 deregulation	 in	 cellular	 models	 of	




and	 the	 relationship	 among	 them	 and	 biological/molecular	 mech‐
anisms	 underlying	NASH/Fibrosis	 severity,	we	 analysed	 transcript	
expression	in	liver	biopsies	of	NAFLD	patients	and	healthy	controls.	














increased	 gene	 and	 protein	 expression	 occurring	 in	 the	 affected	
liver,	needs	to	be	elucidated.	 In	support	of	the	first	hypothesis,	 it	
has	been	reported	that	oxidative	stress	induces	an	increased	eryth‐
rocyte	 susceptibility	 to	 haemolysis	 in	 animal	models	 of	NASH	 30 
and	 in	obese	subjects.39	 In	support	of	the	second	hypothesis,	Liu	
et al	 reported	an	 increased	expression	of	HBA1	and	HBB	 in	 liver	






TGFB2/TGFB2 - OT1 + FIBROSCAN




TGFB2/TGFB2 - OT1 + FIB-4
AUC TGFB2/TGFB2 – OT1: 0,797
AUC FIB-4: 0,819
AUC APRI: 0,759
AUC FIBROSCAN: 0,841    
AUC TGFB2/TGFB2 – OT1 + FIB-4: 0,891
AUC TGFB2/TGFB2 – OT1 + FIBROSCAN: 0,892
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biopsies	 of	 NASH	 patients	 with	 respect	 to	 controls.	 They	 also	
demonstrated	that	H2O2 treatment	of	HepG2	cells	increases	gene	




to	 controls.	However,	 despite	 the	 fact	 that	 palmitate	 is	 a	 known	
oxidative	stress	inducer,40	we	did	not	observe	any	HBA2	gene	ex‐
pression	alteration	in	our	in	vitro	models	and	we	were	not	able	to	
detect	HBA2	expression	 in	 culture	medium.	Probably,	 in	NAFLD,	
the	main	contribution	of	the	increase	in	HBA2	gene	expression	is	
given	 by	 other	 cell	 types,	 different	 from	 hepatocytes,	 inside	 the	
affected	liver	tissue.
Although	 any	 direct	 link	 among	UBE2V1	 gene	 expression	 and	
NAFLD	has	not	been	reported,	UBE2V1	is	involved	in	non‐canonical	




RP11‐128N14.5	 in	NAFLD.	RP11‐128N14.5	 is	 a	 long	 intronic	RNA	
transcribed	 in	 the	 same	 direction	 of	 its	 protein‐coding	 host	 gene	
RAP2A.	RP11‐128N14.5,	 as	already	 reported	 for	 several	 lncRNAs,	
could	have	a	role	in	the	epigenetic	regulation	of	its	host	gene	locus.	
There	are	no	published	data	on	the	association	between	the	RAP2A	
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